Conference Coverage

Jury still out on effect of systemic psoriasis meds on MI risk

Publish date: September 9, 2014

 

EXPERT ANALYSIS AT PDA 2014

References

Dr. Kalb disclosed that he is an investigator and/or consultant for AbbVie, Amgen, Celgene, Dermira, Janssen, Leo, Merck, Pfizer, and Taro. He is also on the dermatology safety monitoring board for ApoPharma and Eli Lilly.

dbrunk@frontlinemedcom.com

On Twitter @dougbrunk

Pages

Recommended Reading

First comorbidity guidelines drafted for psoriatic arthritis
MDedge Rheumatology
First comorbidity guidelines drafted for psoriatic arthritis
MDedge Rheumatology
Patients with psoriatic arthritis perform accurate joint counts
MDedge Rheumatology
New guidelines proposed for nail involvement in psoriatic arthritis
MDedge Rheumatology
Conventional DMARDs may be excluded from psoriatic arthritis enthesitis guidelines
MDedge Rheumatology
Multicenter cooperative psoriatic arthritis study group formed
MDedge Rheumatology
Link between autoimmune therapy, preterm birth is largely due to confounding
MDedge Rheumatology
Infliximab may carry a higher infection rate in psoriasis patients
MDedge Rheumatology
Anti-adalimumab antibodies mean poorer outcomes in psoriatic arthritis
MDedge Rheumatology
Psoriasis patients post above-average cancer rates
MDedge Rheumatology